Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (71-80 of 283) with videos related to

Pageof 29
Sort By:
Transfusion|January 10, 2006
Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usageAarti Oza, Chris Hallemeier, Lawrence Goodnough, et al.
Blood Cancer Journal|August 22, 2019
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapyBarbara Muz, Feda Azab, Mark Fiala, et al.
International Journal of Hematology|February 4, 2014
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AMLGiridharan Ramsingh, Peter Westervelt, Ali McBride, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2019
Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass StudyScott R Goldsmith, Mark A Fiala, James Dukeman, et al.
Experimental Hematology|January 13, 2009
Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myelomaJulie O'Neal, Feng Gao, Anjum Hassan, et al.
Leukemia & Lymphoma|May 17, 2017
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistanceBarbara Muz, Hubert D Kusdono, Feda Azab, et al.
Bone Marrow Transplantation|April 20, 2021
Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78Mark A Fiala, Justin King, Daniel Feinberg, et al.
The Journal of Clinical Investigation|July 4, 2012
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stressLiang Chu, Mack Y Su, Leonard B Maggi, et al.
Transplantation and Cellular Therapy|September 23, 2023
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter TrialMichael Slade, Mark A Fiala, Marie Kirchmeyer, et al.
American Journal of Hematology|January 23, 2016
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemiaIrene M Ghobrial, David S Siegel, Ravi Vij, et al.
Pageof 29

Showing results (71-80 of 283) with videos related to

Sort By:
Pageof 29
Transfusion|January 10, 2006
Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usageAarti Oza, Chris Hallemeier, Lawrence Goodnough, et al.
Blood Cancer Journal|August 22, 2019
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapyBarbara Muz, Feda Azab, Mark Fiala, et al.
International Journal of Hematology|February 4, 2014
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AMLGiridharan Ramsingh, Peter Westervelt, Ali McBride, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2019
Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass StudyScott R Goldsmith, Mark A Fiala, James Dukeman, et al.
Experimental Hematology|January 13, 2009
Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myelomaJulie O'Neal, Feng Gao, Anjum Hassan, et al.
Leukemia & Lymphoma|May 17, 2017
Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistanceBarbara Muz, Hubert D Kusdono, Feda Azab, et al.
Bone Marrow Transplantation|April 20, 2021
Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78Mark A Fiala, Justin King, Daniel Feinberg, et al.
The Journal of Clinical Investigation|July 4, 2012
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stressLiang Chu, Mack Y Su, Leonard B Maggi, et al.
Transplantation and Cellular Therapy|September 23, 2023
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter TrialMichael Slade, Mark A Fiala, Marie Kirchmeyer, et al.
American Journal of Hematology|January 23, 2016
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemiaIrene M Ghobrial, David S Siegel, Ravi Vij, et al.
Pageof 29